Compounds > carboxyifosfamide

Page last updated: 2024-12-07

carboxyifosfamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carboxyifosfamide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	124143
CHEMBL ID	161296
CHEBI ID	80564
MeSH ID	M0177513

Synonyms (12)

Synonym
53459-52-2
carboxyifosfamide
3-bis(2-chloroethylamino)phosphoryloxypropanoic acid
CHEMBL161296
3-({bis[(2-chloroethyl)amino]phosphoryl}oxy)propanoic acid
chebi:80564 ,
ft23dmv6r4 ,
propanoic acid, 3-((bis((2-chloroethyl)amino)phosphinyl)oxy)-
unii-ft23dmv6r4
3-((bis((2-chloroethyl)amino)phosphinyl)oxy)propanoic acid
DTXSID30201624
Q27149608

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" These results indicate that there is no identifiable pharmacokinetic basis for insistence on either bolus or infusional methods of IFOS administration."	( The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. Brennan, C; Hartley, JM; Nicholson, PW; Singer, JM; Souhami, RL, 1998)	0.3

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
phosphorodiamide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

Pathway	Proteins	Compounds
Ifosfamide Action Pathway	8	21
Ifosfamide Metabolism Pathway	8	21

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID7969	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7771	Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7967	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7821	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7772	Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7617	Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7973	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7971	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7968	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7770	Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7773	Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7970	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7615	Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7614	Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7972	Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
AID7616	Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide	1983	Journal of medicinal chemistry, May, Volume: 26, Issue:5	Stereospecific synthesis of chiral metabolites of ifosfamide and their determination in the urine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	4 (66.67)	18.2507
2000's	1 (16.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.53 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.72 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (14.29%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (71.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
ifosfamide [no description available]	4.62	6	1	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
acrolein [no description available]	7.01	1	0	enal	herbicide; human xenobiotic metabolite; toxin
isophosphamide mustard isophosphamide mustard: antitumor metabolite of ifosfamide; palifosfamide-tris is a salt with tris; structure in first source	4.28	4	1	phosphorodiamide
dechloroethylcyclophosphamide dechloroethylcyclophosphamide: structure given in first source; RN given refers to parent cpd	4.05	3	1	phosphorodiamide
dechloroethylifosfamide dechloroethylifosfamide: RN given refers to parent cpd	4.05	3	1	organonitrogen heterocyclic compound; organophosphorus compound
4-hydroxyifosfamide [no description available]	1.96	1	0	ifosfamides

Condition	Indicated	Relationship Strength	Studies	Trials
Cerebral Primitive Neuroectodermal Tumor [description not available]	0	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	0	1.98	1	0
Ewing Sarcoma [description not available]	0	3.78	2	1
Osteogenic Sarcoma [description not available]	0	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	1.98	1	0
Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)	0	1.98	1	0
Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.	0	3.78	2	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	0	1.98	1	0
Neuroectodermal Tumors, Primitive A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)	0	1.98	1	0
Sarcoma, Epithelioid [description not available]	0	3.38	1	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	0	3.38	1	1